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Abstract
BACKGROUND: The aim of this study is to investigate the prevalence and prognostic impact of β-catenin and cyclin
D1 expression in colorectal carcinoma (CRC) patients. METHOD: We evaluated immunohistochemial expression of
β-catenin and cyclin D1 using 2-mm cores from 220 CRC patients for tissue microarray, and its significance was
statistically evaluated. RESULT: Positive expression of β-catenin and cyclin D1 was found in 72.5% (158 of 218 cases)
and 59.4% (129 of 217 cases) of CRC patients, respectively. Expression of β-catenin was significantly correlated with
tumor location (P= .017), differentiation (P= .010), lymph nodemetastasis (P= .032), preoperative carcinoembryonic
antigen level (P= .032), and cyclin D1 expression (P= .005). Expression of cyclin D1 was significantly correlated with
recurrence and/or metastasis (P = .004). In univariate analysis, β-catenin expression predicted more favorable overall
survival (P = .022) and cyclin D1 expression predicted both more favorable overall survival and relapse-free survival
(P= .004 and P= .006, respectively). Multivariate analysis showed that tumor stage and expression of cyclin D1 were
independent prognostic factors significantly associated with overall survival and relapse-free survival. CONCLUSION:
This study shows that expression of β-catenin and cyclin D1 is associated with favorable clinicopathologic variables
and it is a clinically significant prognostic indicator for CRC patients.
Translational Oncology (2012) 5, 370–378
Introduction
Colorectal carcinoma (CRC) is the third most common malignant
tumor worldwide, with an incidence of 1,230,000 cases and
610,000 deaths annually, making it the fourth most common cause
of cancer deaths throughout the world [1]. Recently, there were con-
siderable advances in diagnosis and treatment of CRCs. However,
CRC is still associated with a high rate of incidence and mortality.
The 5-year survival for CRC is less than 60% in Europe, and about
one third of patients with CRC die from it [2].
The most commonly mutated gene in all CRCs is the adenomatous
polyposis coli (APC ) tumor suppressor gene that produces the APC
protein [3]. Because the APC protein is a controller on the accumula-
tion of β-catenin protein, loss of functional APC protein results in the
accumulation of β-catenin [4]. β-Catenin is a member of the cadherin-
catenin complex that mediates homotypic cell-cell adhesion [5]. Accu-
mulated β-catenin is translocated into the nucleus, binds to DNA, and
activates genes that are responsive to transcription factors of the T-cell
factor/lymphoid enhancer factor family [6,7], resulting in the tran-
scription of target genes such as cyclin D1 and matrix metalloproteinase
[8,9]. Clinical significance of β-catenin expression in CRC was contro-
versial. In some studies, expression of β-catenin was regarded as a fac-
tor of unfavorable prognosis in CRC [10,11], whereas other studies
reported that it had no significant association with clinicopathologic
factors [12].
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Cyclin D1 belongs to the highly conserved cyclin family and plays
a key role in cell cycle control, particularly in the transition from G1 to
S phase [13]. Cyclin D1 can carry out multiple functions as an oncogene,
by enhancing several processes during malignant cell transformation,
including abnormal growth, angiogenesis, and resistance to apoptosis
[14]. In addition, cyclin D1 is a target gene of the WNT/β-catenin path-
way. It has been suggested that cyclin D1 transactivation secondary to
APC or β-catenin mutations participates in colonic cancer initiation
[8,15]. Overexpression of cyclin D1 occurs in one third or more of
CRCs [16–22]. Though the role of cyclin D1 in cell cycle progression
is relatively well established, there are some controversies on the relation
of cyclin D1 expression and clinical outcome in CRCs. Some studies
have demonstrated that cyclin D1 expression was associated with poor
prognosis [16,17]; however, other studies have shown good prognosis
associated with cyclin D1 expression [18,19]. The other studies demon-
strated no prognostic significance of cyclin D1 expression [20–22].
Many studies have investigated the clinicopathologic and prognostic
significance of β-catenin as well as cyclin D1 in CRCs; however, the
results were quite different according to the studies and there was no
investigation on the expression between β-catenin and cyclin D1 in
CRCs. The aim of the present study is to determine the expression
of β-catenin and cyclin D1 in CRC patients and to evaluate their
correlation with the clinicopathologic variables and their prognostic
impact on CRC patients.
Materials and Methods
Patients and Specimens
Two hundred twenty cases of colorectal adenocarcinoma patients
who had surgical resection in Chonbuk National University Hospital
between January 2003 and December 2004 were included in the
present study. All of 220 patients had received complete surgical re-
section of the tumor with microscopically clear resection margins.
Histologic findings of all cases were reviewed by two authors (Y.N.K.
and H.S.P.) who were blinded to each other’s evaluation. Among
the 220 patients, 111 patients had received surgical resection only
and 109 patients had received surgical resection and postoperative
adjuvant chemotherapy (78 patients received 5-fluorouracil (5-FU),
14 patients received 5-FU plus folic acid and oxaliplatin, 6 patients
received irinotecan, 5 patients received 5-FU plus folic acid, 4 patients
received enteric-coated granular chemotherapeutic drug composed of
tegafur and uracil (UFT-E), and 2 patients received oxaliplatin). The
tissue microarray blocks were produced by using formalin-fixed paraffin-
embedded tissue blocks. Two cores with a diameter of 2.0mmwere taken
from colorectal adenocarcinoma in each cases. In addition, 20 cases of
noncancerous colorectal mucosa were also included. The patients were
grouped according to their age, sex, location, tumor size, differentiation,
lymphovascular invasion, presence of lymph node metastasis, presence
of recurrence and/or distant metastasis, stage (I and II versus III and IV),
preoperative serum carcinoembryonic antigen (CEA) levels, and pre-
operative serum CA19-9 levels. The present study was approved by
the local ethics committee of the institutional review board of Chonbuk
National University Hospital.
Immunohistochemical Staining and Scoring
Immunohistochemistry was done by using the tissue microarray
block. Briefly, after deparaffinization, tissue sections were treated with
a microwave antigen retrieval procedure in 0.01 M sodium citrate
buffer for 12 minutes. After blocking endogenous peroxidase, sections
were incubated with Protein Block Serum-Free (Dako, Carpinteria,
CA) at room temperature for 10 minutes to block nonspecific staining;
the sections were then incubated for 2 hours at room temperature with
anti–β-catenin (1:100, clone 14/β-catenin; BD Bioscience, San Jose,
CA) and anti–cyclin D1 (1:50, clone SP4; Thermo Fisher Scientific
Inc, Kalamazoo, MI) antibodies. Peroxidase activity was detected with
the enzyme substrate 3-amino-9-ethyl carbazole. For the negative
controls, sections were treated in the same manner, except that they
were incubated with TBS without the primary antibody. Immuno-
histochemical analysis was done by three authors (K.Y.J., Y.N.K.,
and H.S.P.) without knowledge of the clinicopathologic informa-
tion. Three authors simultaneously evaluated the slides for immuno-
histochemical stain by using the multiviewing microscope. In every
case, the consensus for immunohistochemical score was reached after
discussion on the intensity and area of immunostain by three authors.
During the immunostaining, there were unexpected loss of tissue cores
in two cases for β-catenin and three cases for cyclin D1. Accordingly,
218 cases of CRCs were immunostained for β-catenin and 217 cases
of CRCs for cyclin D1. Each case was evaluated by estimating the per-
centages of tumor cells that stained positively for each marker. Immu-
nostaining for β-catenin and cyclin D1 was considered positive if
≥30% of the tumor cells in either core were stained with an antibody.
Paraffin-embedded tissue samples for immunohistochemistry were
provided by the Chonbuk National University Hospital, a member
of the National Biobank of Korea, which is supported by the Ministry
of Health, Welfare and Family Affairs.
Statistical Analysis
The end points of interest were relapse-free survival and overall
survival. The end point of follow-up was the date of the last contact
or the date of death through November 2011. Overall survival was
calculated as the time from diagnosis to the date of death or last
contact. Patients who were alive at last contact were treated as cen-
sored for overall survival analysis. Relapse-free survival was calculated
from the time of diagnosis to the date of recurrence, metastasis,
death, or last contact. Patients who were alive at last contact and
who had not recurred and not metastasized were treated as censored
for relapse-free survival analysis. The associations between staining
index and other categorical factors potentially predictive of prognosis
were analyzed using Pearson χ2 test. Univariate and multivariate Cox
proportional hazards regression analysis was done to estimate the
impact of clinicopathologic factors and expression of each marker on
relapse-free survival and overall survival. Kaplan-Meier survival curves
were constructed to further illustrate the impact of overall survival
when indicated. SPSS software (version 18.0; SPSS Inc, Chicago, IL)
was used throughout for statistical analysis, and P < .05 was considered
statistically significant.
Results
Association of β-Catenin and Cyclin D1 Expression with
Clinicopathologic Characteristics of CRCs
The clinicopathologic features are summarized in Table 1. Immuno-
histochemical staining of β-catenin and cyclin D1 in normal colorectal
mucosa and colorectal adenocarcinoma tissues are shown in Figure 1.
Expression of β-catenin and cyclin D1 was not identified in all 20 cases
of normal colorectal mucosa. In colorectal adenocarcinoma, immuno-
reactivity for cyclin D1 was found primarily in the nuclei. Although
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β-catenin was expressed in the nuclei, membrane, and cytoplasm, we
evaluated nuclear β-catenin expression only. As shown in Table 1, posi-
tive expression of β-catenin was found in 72.5% (158 of 218 cases)
and of cyclin D1 in 59.4% (129 of 217 cases) of colorectal adeno-
carcinoma patients. Expression of β-catenin was significantly correlated
with tumor location (P = .017), differentiation (P = .010), lymph node
metastasis (P = .032), preoperative CEA level (P = .032), and cyclin
D1 expression (P = .005). Stage showed a tendency to be correlated
with β-catenin expression (P = .066). There was no correlation be-
tween β-catenin expression and age, sex, tumor size, lymphovascular
invasion, recurrence and/or metastasis, and preoperative CA19-9 level.
Expression of cyclinD1was also significantly correlated with recurrence
and/ormetastasis (P = .004). There was no correlation between cyclinD1
expression and age, sex, location, tumor size, lymphovascular invasion,
lymph node metastasis, stage, preoperative CEA level, and preoperative
CA19-9 level.
Expression of β-Catenin and Cyclin D1 in Colorectal
Adenocarcinoma Correlates with Favorable Relapse-free
Survival and Overall Survival
Univariate Cox proportional hazard analysis of the expression of
β-catenin and cyclin D1 and their relationship with relapse-free sur-
vival and overall survival are shown in Table 2. Tumor size larger
than 4.0 cm (P = .011 and P = .004), poorly differentiated tumor
(P < .001 and P = .006, Figure 2A), presence of lymph node metas-
tasis (P < .001 and P = .002), advanced stage (III and IV, P < .001
and P < .001, Figure 2B), preoperative CEA level more than 5.0 ng/
ml (P = .002 and P < .001), and preoperative CA19-9 level more
than 37.0 U/ml (P < .001 and P < .001) predicted both shorter over-
all survival and relapse-free survival, respectively. In addition, age more
than 65 years (P = .009) predicted shorter overall survival and presence
of lymphovascular invasion (P = .008) predicted shorter relapse-free
survival. However, expression of β-catenin (P = .022, Figure 2C) also
predicted more favorable overall survival and expression of cyclin D1
(P = .004 and P = .006, Figure 2D) predicted both more favorable over-
all survival and relapse-free survival, respectively. There was no prog-
nostic significance between the patients treated with surgery only and
the patients who received adjuvant chemotherapy after surgical resec-
tion (overall survival, P = .625; relapse-free survival, P = .482; Table 2).
When we separately considered the patients according to the treatment
modality, the expression of β-catenin predicted more favorable overall
survival in patients who received adjuvant chemotherapy (P = .018;
Figure 3A). Cyclin D1 expression was also significantly correlated with
better overall survival (P < .001) and relapse-free survival (P = .03) in
the patients who received adjuvant chemotherapy (Figure 3B). How-
ever, the expression of β-catenin or cyclin D1 was not associated with
overall survival (β-catenin, P = .422; cyclin D1, P = .867) or relapse-
free survival (β-catenin, P = .539; cyclin D1, P = .069) in the patients
treated with surgical resection only.
Table 1. Clinicopathologic Variables and the Expression Status of β-Catenin and Cyclin D1.
β-Catenin Cyclin D1
No. of Cases Negative (%) Positive (%) P Value No. of Cases Negative (%) Positive (%) P Value
Age (years) 0.290 0.074
≤65 118 29 (24.6) 89 (75.4) 117 41 (35.0) 76 (65.0)
>65 100 31 (31.0) 69 (69.0) 100 47 (47.0) 53 (53.0)
Gender 0.369 0.791
Male 134 34 (25.4) 100 (74.6) 133 53 (39.8) 80 (60.2)
Female 84 26 (31.0) 58 (69.0) 84 35 (41.7) 49 (58.3)
Location 0.017 0.327
Rt. colon 51 22 (43.1) 29 (56.9) 50 16 (32.0) 34 (68.0)
Lt. colon 64 14 (21.9) 50 (78.1) 64 26 (40.6) 38 (59.4)
Rectum 103 24 (23.3) 79 (76.7) 103 46 (44.7) 57 (55.3)
Tumor size (cm) 0.623 0.942
≤4.0 82 21 (25.6) 61 (74.4) 82 33 (40.2) 49 (59.8)
>4.0 136 39 (28.7) 97 (71.3) 135 55 (40.7) 80 (59.3)
Differentiation 0.010 0.526
Well/moderate 60 50 (83.3) 10 (16.7) 198 79 (39.9) 119 (60.1)
Poor 158 149 (94.3) 9 (5.7) 19 9 (47.4) 10 (52.6)
Lymphovascular invasion 0.166 0.609
Absent 170 43 (25.3) 127 (74.7) 169 67 (39.6) 102 (60.4)
Present 48 17 (35.4) 31 (64.6) 48 21 (43.8) 27 (56.3)
Lymph node metastasis 0.032 0.188
Absent 123 27 (22.0) 96 (78.0) 123 45 (36.6) 78 (63.4)
Present 91 32 (35.2) 59 (64.8) 90 41 (45.6) 49 (54.4)
Recurrence/metastasis 0.564 0.004
No 200 54 (27.0) 146 (73.0) 199 75 (37.7) 124 (62.3)
Yes 18 6 (33.3) 12 (66.7) 18 13 (72.2) 5 (27.8)
Stage 0.066 0.308
I and II 120 27 (22.5) 93 (77.5) 120 45 (37.5) 75 (62.5)
III and IV 98 33 (33.7) 65 (66.3) 97 43 (44.3) 54 (55.7)
Preoperative CEA (ng/ml) 0.032 0.782
≤5.0 141 32 (22.7) 109 (77.3) 141 54 (38.3) 87 (61.7)
>5.0 68 25 (36.8) 43 (63.2) 67 27 (40.3) 40 (59.7)
Preoperative CA19-9 (U/ml) 0.380 0.390
≤37.0 136 39 (28.7) 97 (71.3) 135 51 (37.8) 84 (62.2)
>37.0 21 8 (38.1) 13 (61.9) 21 10 (47.6) 11 (52.4)
Cyclin D1 0.005
Negative 59 33 (55.9) 26 (44.1)
Positive 158 55 (34.8) 103 (65.2)
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Expression of Cyclin D1 in Colorectal Adenocarcinoma Is an
Independent Prognostic Factor for Good Survival Outcome
Multivariate analysis was performed using 156 patients with com-
plete information for all variables. Variables considered in the analysis
were the age, sex, location, tumor size, differentiation, lymphovascular
invasion, stage, preoperative CEA level, preoperative CA19-9 level,
β-catenin expression, and cyclin D1 expression. From the multivariate
analysis, only stage and expression of cyclin D1 were independent
prognostic factors significantly associated with both overall survival
and relapse-free survival (Table 3). Advanced stage (III and IV) was
an independent prognostic factor significantly associated with poor
overall survival (adjusted hazard ratio (HR), 2.540; 95% confidence
interval (CI), 1.388–4.649; P = .003) and relapse-free survival (adjusted
HR, 2.857; 95%CI, 1.421–5.745;P = .003). Colorectal adenocarcinomas
with cyclin D1 expression were associated with a significantly higher
overall survival (adjusted HR, 0.477; 95% CI, 0.279–0.817; P = .007)
and relapse-free survival (adjusted HR, 0.508; 95% CI, 0.282–0.916,
P = .024). In addition, age more than 65 years, poorly differentiated
tumor, and preoperative CA19-9 level more than 37.0 U/ml were
also independent prognostic factors significantly associated with
overall survival. Among the patients who received adjuvant chemo-
therapy, expression of β-catenin was an independent prognostic
factor significantly associated with good overall survival (adjusted
HR, 0.406; 95% CI, 0.194–0.850, P = .017). Moreover, expression
of cyclin D1 in patients who received adjuvant chemotherapy was
also an independent prognostic factor significantly associated with
good overall survival (adjusted HR, 0.025; 95% CI, 0.092–0.457,
P < .001) and relapse-free survival (adjusted HR, 0.452; 95% CI,
0.212–0.963, P < .040).
Discussion
In this study, we examined the immunohistochemical expression of
β-catenin and cyclin D1 in colorectal adenocarcinoma tissues, their
correlation with clinicopathologic variables, and their prognostic sig-
nificance. This study has shown that 1) 72.5% of colorectal adeno-
carcinomas expressed β-catenin and its expression was significantly
correlated with favorable clinicopathologic variables such as well or
moderate differentiation, absence of lymph node metastasis, low pre-
operative serum CEA level, and cyclin D1 expression; 2) 59.4% of
colorectal adenocarcinomas expressed cyclin D1 and its expression
was significantly correlated with favorable clinicopathologic variables
such as absence of recurrence and/or metastasis; 3) expression of
cyclin D1 was associated with a significantly longer overall survival
and relapse-free survival in colorectal adenocarcinoma patients. Though
expression of β-catenin was also a favorable prognostic factor of colorec-
tal adenocarcinoma by univariate analysis, it was not an independent
prognostic indicator by multivariate analysis. It may be due to high
correlation between cyclin D1 expression and β-catenin expression.
Taken together, our findings indicate that cyclin D1 and β-catenin
may be significant favorable prognostic indicators for colorectal adeno-
carcinoma patients.
β-Catenin is present in different intracellular localizations that are
associated with its distinct functions. β-Catenin is part of adherence
junctions when bound to the cell membrane [5], whereas it interacts
with DNA-binding proteins of the T-cell factor/lymphoid enhancer
factor family and acts as a transcriptional activator when located in
the nucleus [6,7]. It is well known that the nuclear localization of
β-catenin is partially regulated by the WNT signaling pathway. In the
presence of WNT signaling, multiprotein complexes such as APC,
Figure 1. Immunohistochemical staining for β-catenin (A–C) and cyclin D1 (D–F) in normal colorectal mucosa and colorectal adeno-
carcinoma. Normal mucosa is negative for β-catenin (A) and cyclin D1 (D). In colorectal adenocarcinoma specimens, β-catenin is posi-
tive in the nuclei and cytoplasm (B), whereas cyclin D1 show nuclear positivity (E). Some colorectal adenocarcinomas are negative for
β-catenin (C) and cyclin D1 (F). Original magnification, ×400.
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axin, and glycogen synthase kinase 3β that are usually responsible for
the cytoplasmic degradation of β-catenin become inactive [4,23,24].
As a result, β-catenin is accumulated in the cytoplasm and can be trans-
located into the nucleus where it leads to subsequent activation of cyclin
D1. The localization of β-catenin by immunohistochemistry in CRC
has shown wide variability in terms of proportion with nuclear, cyto-
plasmic, or membranous staining [25,26]. In this study, we considered
nuclear expression of β-catenin as positive staining and this is reasonable
because β-catenin plays the transcriptional role in the nucleus. In several
previous studies, the results of correlation of β-catenin expression and
colon cancer prognosis or progression were inconsistent. Hugh et al.
[11] reported that nuclear expression of β-catenin was independently
predictive of a shorter survival. Chung et al. [27] reported that nuclear
expression of β-catenin did not have a significant correlation with sur-
vival of CRC, whereas nuclear expression of phosphor–β-catenin was
associated with a better prognosis. Horst et al. [28] reported that colon
cancers with no nuclear β-catenin expression had the worst prognosis
and this is concordant with our result. Moreover, nuclear expression
of β-catenin has been reported to be correlated with good prognosis
in hepatocellular carcinoma and ovarian carcinoma [29,30]. These
findings also support that nuclear expression of β-catenin is associated
with good prognosis as in our result.
Cyclin D1 overexpression in tumors can be acquired by several
mechanisms such as CCLND1 gene amplification, increased transcrip-
tion by constitutive activation of transcriptional regulators, or increased
mRNA or protein stability [31]. Though there were several previous
studies that have examined the relationship between cyclin D1 expres-
sion and clinical outcome in colon cancer [16–22], they have yielded
Table 2. Clinicopathologic Factors and Their Effects on Overall Survival and Relapse-free Survival by Univariate Cox Proportional Hazard Regression Analysis.
No. of Cases Overall Survival Relapse-free Survival
HR (95% CI) P Value HR (95% CI) P Value
Overall colorectal adenocarcinoma (n = 220)
Age
≤65 years 118 1 1
>65 years 102 1.895 (1.175–3.057) 0.009 1.194 (0.717–1.990) 0.496
Gender
Male 136 1 1
Female 84 0.861 (0.527–1.407) 0.550 0.935 (0.561–1.558) 0.797
Location
Rt. colon 52 1
Lt. colon 64 0.445 (0.212–0.936) 0.033 0.669 (0.318–1.406) 0.228
Rectum 104 1.003 (0.580–1.737) 0.990 1.073 (0.582–1.975) 0.822
Tumor size
≤4.0 cm 83 1 1
>4.0 cm 137 2.006 (1.172–3.434) 0.011 2.419 (1.331–4.398) 0.004
Differentiation
Well/Moderate 201 1 1
Poor 19 3.324 (1.741–6.347) <0.001 2.695 (1.321–5.497) 0.006
Lymphovascular invasion
Absent 172 1 1
Present 48 1.624 (0.965–2.732) 0.068 2.053 (1.210–3.482) 0.008
Lymph node metastasis
Absent 125 1 1
Present 91 2.410 (1.485–3.909) <0.001 2.242 (1.337–3.758) 0.002
Recurrence/Metastasis
No 159 1
Yes 61 6.735 (4.089–11.093) <0.001
Stage
I and II 122 1 1
III and IV 98 2.836 (1.719–4.680) <0.001 3.485 (2.009–6.047) <0.001
Adjuvant chemotherapy
No 111 1 1
Yes 109 0.889 (0.554–1.426) 0.625 1.199 (0.723–1.988) 0.482
Preoperative CEA
≤5.0 ng/ml 143 1 1
>5.0 ng/ml 68 2.175 (1.331–3.553) 0.002 2.524 (1.507–4.227) <0.001
Preoperative CA19-9
≤37.0 U/ml 138 1 1
>37.0 U/ml 21 3.778 (2.088–6.833) <0.001 4.070 (2.174–7.620) <0.001
β-Catenin
Negative 60 1 1
Positive 158 0.558 (0.339–0.918) 0.022 0.660 (0.387–1.128) 0.129
Cyclin D1
Negative 88 1 1
Positive 129 0.494 (0.306–0.796) 0.004 0.491 (0.296–0.813) 0.006
Patients who received adjuvant chemotherapy (n = 109)
β-Catenin
Negative 30 1 1
Positive 79 0.440 (0.224–0.866) 0.018 0.597 (0.295–1.208) 0.151
Cyclin D1
Negative 42 1 1
Positive 66 0.261 (0.131–0.521) <0.001 0.474 (0.241–0.932) 0.030
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Figure 2. Survival analysis in colorectal adenocarcinoma. (A) Overall survival and relapse-free survival in well/moderately differentiated and
poorly differentiated groups. (B) Overall survival and relapse-free survival in low clinical stage (I and II) and high clinical stage (III and IV) groups.
(C) Relationship of nuclearβ-catenin expression to overall survival and relapse-free survival. (D) Relationship of nuclear cyclinD1expression to
overall survival and relapse-free survival. P values were determined by comparing survival distributions using the log-rank test.
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Figure 3. Survival analysis in colorectal adenocarcinoma patients who had received adjuvant chemotherapy. (A) Relationship of nuclear
β-catenin expression to overall survival and relapse-free survival. (B) Relationship of nuclear cyclin D1 expression to overall survival and
relapse-free survival. P values were determined by comparing survival distributions using the log-rank test.
Table 3. Clinicopathologic Factors and Their Effects on Overall Survival and Relapse-free Survival by Multivariate Cox Proportional Hazard Regression Analysis.
Overall Survival Relapse-free Survival
HR (95% CI) P value HR (95% CI) P value
Overall colorectal adenocarcinoma (n = 156)
Age
≤65 years 1 1
>65 years 2.185 (1.264–3.777) 0.005 1.012 (0.561–1.825) 0.967
Differentiation
Well/Moderate 1 1
Poor 2.690 (1.233–5.869) 0.013 1.753 (0.720–4.270) 0.216
Stage
I and II 1 1
III and IV 2.540 (1.388–4.649) 0.003 2.857 (1.421–5.745) 0.003
Preoperative CA19-9
≤37.0 U/ml 1 1
>37.0 U/ml 3.182 (1.661–6.096) <0.001 1.764 (0.786–3.959) 0.169
Cyclin D1
Negative 1 1
Positive 0.477 (0.279–0.817) 0.007 0.508 (0.282–0.916) 0.024
Patients who received adjuvant chemotherapy (n = 82)
β-Catenin
Negative 1 1
Positive 0.406 (0.194–0.850) 0.017 1.167 (0.478–2.847) 0.734
Cyclin D1
Negative 1 1
Positive 0.205 (0.092–0.457) <0.001 0.452 (0.212–0.963) 0.040
Variables include age, sex, location, tumor size, differentiation, lymphovascular invasion, stage, preoperative CEA level, preoperative CA19-9 level, β-catenin expression, and cyclin D1 expression.
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inconsistent results. Some studies have demonstrated that cyclin D1 ex-
pressionwas associatedwith poor prognosis [16,17]; however, other stud-
ies have shown that cyclin D1 expression was associated with good
prognosis as in the present study [18,19]. The other studies demonstrated
no prognostic significance of cyclin D1 expression [20–22]. The contro-
versial results in the expression of β-catenin and cyclin D1 may be due to
differences in sample sizes, intrinsic tumor heterogeneity, methods of
scoring criteria, and antibodies used to access their expression in CRCs.
In general, oncogene activation or tumor suppressor gene inactiva-
tion is associated with aggressive tumor behavior. However, this hy-
pothesis is not always true as shown in an example that microsatellite
instability, which is known to cause inactivation of tumor suppressor
genes, is associated with better patient outcome [32]. Though the reason
why cyclin D1 expression is associated with good prognosis is unclear,
Ogino et al. [19] have proposed the possibility that cyclin D1–negative
cancers might have bypassed the cyclin D1 activation, which might
cause more aggressive behavior than cyclin D1–activated cancers through
accumulation of multiple genetic and epigenetic events during colorec-
tal carcinogenesis. Moreover, association between cyclin D1 expression
and good prognosis have been described in non–small cell lung cancer,
breast cancer, and bladder cancer [33–35]. Nosho et al. [36] have
reported that cyclin D1 was frequently overexpressed in microsatellite
unstable CRCs that is known to have a better prognosis than micro-
satellite stable CRCs. This finding also supports our result that cyclin
D1 overexpression is associated with good prognosis. In addition, when
we performed survival analysis in the subgroup of patients according
to the treatment modality, the expression of cyclin D1 predicted better
overall survival and relapse-free survival in the patients who received
adjuvant chemotherapy but not in the patients treated with surgery only.
Thus, we can infer that colorectal adenocarcinomas expressing cyclin
D1 may predict better response to adjuvant chemotherapy than those
that did not. This assumption is compatible with the result of recent
study that reported increased chemosensitivity in cyclin D1 overexpres-
sing myeloma cell line [37]. However, more studies are needed to deter-
mine the effect of cyclin D1 expression on the chemotherapeutic
response in colorectal adenocarcinoma.
In conclusion, expression of β-catenin and cyclin D1 was associated
with favorable clinicopathologic variables of colorectal adenocarcinoma
and with good prognosis of colorectal adenocarcinoma patients. Al-
though the role of β-catenin and cyclin D1 in tumor progression is
not clear, our data suggest that their expression is a clinically significant
prognostic indicator for colorectal adenocarcinoma patients.
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